Makale detayı · 2025
The Relationship of Tumor Marker Panel with Tumor Size and Histopathological Results in Borderline Ovarian Tumor
Dergi
Bezmialem ScienceISSN 2148-2373
- Yıl
- 2025
- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS YÖKSİS makale kaydı
- YÖKSİS dergi adı Bezmialem Science
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
İngilizce (OpenAlex)
Objective: This retrospective, cross-sectional, and single-center study aimed to explore the correlation between preoperative tumor marker panel levels, tumor size, and histopathological features in borderline ovarian tumors (BOTs). Methods: Sixty-seven patients, with confirmed pathologic results indicating BOTs, were included. The patients were categorized into two groups based on the type of surgery performed (comprehensive surgery and fertility-sparing surgery). The evaluation encompassed parameters such as tumor size, tumor laterality, histopathological tumor type, and other clinicopathological features. Results: Preoperatively, 32 patients (47.7%) exhibited high cancer antigen (CA) -125, 13 patients (19.4%) high CA 19-9, 3 patients (4.4%) high CA 15-3, 7 patients (10.4%) high carcinoembryonic antigen (CEA), and 2 patients (2.9%) high alpha-fetoprotein (AFP) levels. A statistically significant correlation was observed between tumor size and elevated CEA values (p=0.010). However, no significant correlations were found between tumor size and CA-125, CA 19-9, CA 15-3, and AFP levels. Histopathological types showed a significant correlation with mean tumor diameter; serous, mucinous, and seromucinous (mixed) types had mean tumor diameters of 10.14±4.58 cm, 19.35±9.23 cm, and 10.67±6.17 cm, respectively (p=0.001). Conclusion: Elevated tumor marker levels, especially CEA, may indicate larger tumor sizes, with mucinous BOTs being more associated with larger diameters. However, preoperative increases in tumor marker levels do not reliably predict histopathological typing for clinicians.
Konular
- Ovarian cancer diagnosis and treatment
Birincil konu Ovarian cancer diagnosis and treatment